96 results
8-K
EX-99.1
KA
Kineta Inc
15 May 24
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
4:03pm
space, partially offset by higher activities for KVA12123, our lead product candidate, and CD27 licensing expense.
General and administrative expense … , 2023. The decrease was primarily due to a decrease in personnel costs of $538,000 and other administrative expenses of $328,000, partially offset
8-K
EX-99.1
KA
Kineta Inc
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
for clinical trial development of KVA12123 as well as general corporate purposes, partially offset by $8.6 million net proceeds received from
8-K
EX-99.1
bcsw9getup o1ucq
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
8-K
EX-99.1
cef1 2bav
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.1
tyu4h9kffs3
11 May 23
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
5:20pm
8-K
EX-99.1
j6l8ak
31 Mar 23
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.5
80czwg71r7aek1xd
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.4
bus5sy
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
425
8135uiwj1hwdlr7ca4
14 Nov 22
Business combination disclosure
8:50am
8-K
EX-99.1
bn7hw3o8 i6cy
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am
424B3
cpqzx5pavvoubr
10 Nov 22
Prospectus supplement
4:21pm